Llwytho...
Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with (18)F-FDOPA and (18)F-FDG PET
Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necess...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Nucl Med |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Society of Nuclear Medicine
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6167538/ https://ncbi.nlm.nih.gov/pubmed/29700126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.208744 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|